期刊
MULTIPLE SCLEROSIS AND RELATED DISORDERS
卷 57, 期 -, 页码 -出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.msard.2021.103356
关键词
Neuromyelitis optica spectrum disorder; aquaporin-4-IgG-seronegative; myelin oligodendrocyte glycoprotein-IgG-seropositive; annualized attack rate; inebilizumab; clinical trial
资金
- MedImmune
- Horizon Therapeutics
This study reported the outcomes of AQP4- participants in NMOSD. Only 36% of AQP4 screened participants were considered eligible for randomization. The study evaluated MOG-IgG serology and annualized attack rates, and assessed efficacy by comparing pre-study and on-study AARs.
Background: The N-MOmentum trial, a double-blind, randomized, placebo-controlled, phase 2/3 study of inebilizumab in neuromyelitis optica spectrum disorder (NMOSD), enrolled participants who were aquaporin-4immunoglobulin G (AQP4-IgG)-seropositive (AQP4+) or -seronegative (AQP4-). This article reports AQP4- participant outcomes. Methods: AQP4-IgG serostatus was determined for all screened participants by a central laboratory, using a validated, fluorescence-observation cell-binding assay. Medical histories and screening data for AQP4- participants were assessed independently by an eligibility committee of three clinical experts during screening. Diagnosis of NMOSD was confirmed by majority decision using the 2006 neuromyelitis optica criteria. Myelin oligodendrocyte glycoprotein-immunoglobulin G (MOG-IgG) serology (using a clinically validated, flow cytometry assay) and annualized attack rates (AARs) were evaluated post hoc. Efficacy outcomes were assessed by comparing pre-study and on-study AARs in treated participants. Results: Only 18/50 AQP4 screened participants (36%) were initially considered eligible for randomization; 16 were randomized and received full treatment, 4 to placebo (1 MOG-IgG-seropositive [MOG+]) and 12 to inebilizumab (6 MOG+). The most common reason for failure to pass screening among prospective AQP4-
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据